ArticleInternational journal of general medicine2026
Machine Learning Identification of Metabolism-Related Biomarkers with Diagnostic Potential for Gastric Cancer: Multi-Dimensional Transcriptomic Validation.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: An increasing body of evidence suggests an association between metabolic syndrome and gastric cancer. However, the shared genetic signatures and underlying molecular mechanisms between them remain to be elucidated. Methods: We obtained transcriptomic data for gastric cancer and metabolic syndrome from the GEO, TCGA, and GTEx databases. Using the Limma and WGCNA algorithms respectively, we identified differential genes and co-expression module genes related to metabolic syndrome and gastric cancer. Lasso and SVM were employed to further screen for hub genes, while XGBoost was utilized to enhance the diagnostic value of these hub genes. CIBERSORT and GSVA were applied to assess the correlation among hub genes for immune infiltration and metabolic scores. Single-cell and spatial transcriptomic analyses were conducted to explore cell subpopulations and tissue distribution of hub genes in gastric cancer. We used qPCR experiments to detect expression differences of hub genes between gastric cancer tissues and normal tissues. Results: CSE1L, IL32, and CCDC86 were identified as shared hub genes between metabolic syndrome and gastric cancer. These genes were significantly associated with immune cell infiltration and dysregulated metabolic pathways. Single-cell analysis revealed elevated glycolysis across gastric cancer cell subpopulations, accompanied by enhanced cell-cell interactions. Spatial transcriptomic analysis confirmed the upregulation of hub genes in tumor regions. qPCR further verified significantly higher mRNA expression levels of these genes in gastric cancer tissues than in adjacent normal tissues. Conclusion: CSE1L, IL32, and CCDC86 may represent potential metabolism-related biomarkers associated with gastric cancer and metabolic syndrome. These findings provide additional insight into the molecular links between the two conditions and may support future mechanistic studies and larger-scale clinical validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.